- May 20, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Tecentriq
Synonyms :
Atezolizumab
Class :
Antineoplastics and PD-1/PD-L1 Inhibitors
Dosage Forms & Strengths
Injectable solution
1200 mg per 20 ml
840 mg per 14 ml
Monotherapy:
840
mg
Intravenous (IV)
e
2
weeks
or 1200 mg given IV every three weeks, or 1680 mg given IV every four weeks
Continue the course until disease progression, or unacceptable toxicity occurs
For Monotherapy dosing:
840
mg
Intravenous (IV)
2
weeks
or 1200 mg given IV every three weeks, or 1680 mg given IV every four weeks
Continue the course until disease progression, or unacceptable toxicity occurs
Note:
the first infusion administered for over 60 minutes if well-tolerated, and subsequent infusions administered for over 30 minutes
Combination with platinum-based chemotherapy:
1200 mg given IV every three weeks
Continue the course until disease progression, or unacceptable toxicity occurs
Before chemotherapy, atezolizumab is administered, and bevacizumab is provided on the same day
After completion of 4-6 cycles of chemotherapy, the bevacizumab can be discontinued,
the dosage recommended for atezolizumab is:
840 mg given IV every two weeks or 1200 mg given IV every three weeks, or 1680 mg given IV every four weeks
Continue the course until disease progression, or unacceptable toxicity occurs
Note:
the first infusion administered for over 60 minutes if well-tolerated, and subsequent infusions administered for over 30 minutes
840
mg
Intravenous (IV)
was given on days 1 and 15, followed by protein-bound paclitaxel and 100 mg per m2 IV on Days 1, 8, and 15 for each 28-day course cycle
Continue the course until disease progression, or unacceptable toxicity occurs
Note:
the first infusion administered for over 60 minutes if well-tolerated, and subsequent infusions administered for around 30 minutes
1200
mg
Intravenous (IV)
3
weeks
with carboplatin and etoposide combination
Continue the course until disease progression, or unacceptable toxicity occurs
After completion of 4 cycles of carboplatin and etoposide combination, the recommended dosage of atezolizumab is:
840 mg given IV every two weeks or 1200 mg given IV every three weeks, or 1680 mg given IV every four weeks
Continue the course until disease progression, or unacceptable toxicity occurs
Note:
the first infusion is administered for over 60 minutes if well-tolerated, and subsequent infusions administered for around 30 minutes
1200
mg
Intravenous (IV)
over 1 hr
and followed by 15 mg per kg of bevacizumab on the same day for every three weeks
Continue the course until disease progression, or unacceptable toxicity occurs
if bevacizumab is discontinued for toxicity, the dosage recommended for atezolizumab is:
840 mg given IV every two weeks or 1200 mg given IV every three weeks, or 1680 mg given IV every four weeks
Continue the course until disease progression, or unacceptable toxicity occurs
Note:
the first infusion administered for over 60 minutes if well-tolerated, and subsequent infusions administered for around 30 minutes
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
Adverse drug reactions:
Frequency defined
>10%
Rash
pruritus
Nausea
constipation
diarrhea
abdominal pain
vomiting
Urinary tract infection
Immune related colitis
Decreased appetite
Back/neck pain
Arthralgia
Fatigue
pyrexia
peripheral edema
Dyspnea
cough
<10%
Dyspnea
Pneumonia
Hematuria
Confusional state
Increased creatinine
Hyponatremia
hyperglycemia
Hypoalbuminemia
Immune related pneumonitis
immune related hepatitis
Sepsis
Acute kidney injury
liver enzyme increase
increased ALT
increased AST
Anemia
lymphopenia
increased alkaline phosphatase
Dehydration
intestinal obstruction
Venous thromboembolism
Frequency not defined
Immune-related thyroid disorders
Infusion related reactions
Immune related endocrinopathies
Ocular inflammatory toxicity
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Atezolizumab is an immunotherapy drug responsible for helping the immune system fight cancer. The structure of atezolizumab is a protein that blocks (PDL1 or programmed death-ligand).
It helps increase the life expectancy of cancerous patients.
It is used to treat urinary tract cancer/urothelial carcinoma, non-small cell lung cancer, liver cancer, and skin melanoma.
Side effects may arise due to atezolizumab, including intestinal problems like diarrhea, abdominal pain, dysentery, etc.
The liver problems that may occur are yellowing of skin/eyes, nausea, vomiting, and dark urine.
Other side effects may include hair loss, polyurea, loss of appetite, blurred vision, and anemia.
You should not take the medication if you are pregnant, lactating, or planning to conceive.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
